<DOC>
	<DOC>NCT00109408</DOC>
	<brief_summary>This 2 arm study will assess the safety and efficacy of tocilizumab monotherapy versus methotrexate in patients with active rheumatoid arthritis (RA). Patients will be randomized to receive tocilizumab 8mg/kg iv every 4 weeks plus placebo po weekly, or methotrexate 7.5-20mg po weekly plus placebo iv every 4 weeks. The anticipated time on study treatment is 3-12 months and the target sample size is 500+ individuals.</brief_summary>
	<brief_title>A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patients at least 18 years of age with active RA for at least 3 months; patients of reproductive potential must be using reliable methods of contraception. major surgery (including joint surgery) within 8 weeks before entering study or planned major surgery within 6 months after entering study; treatment with methotrexate (MTX) within 6 months of entering study; patients who have stopped previous MTX treatment due to toxicity or lack of response; women who are pregnant or breastfeeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>